Innate Pharma to Present at AACR Oncology Event
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IPHA?
Source: Newsfilter
- Key Presentation Opportunity: Innate Pharma's COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego, California, showcasing the company's innovative advancements in oncology drug development, which is expected to attract attention from investors and analysts.
- Clinical Pipeline Recognition: This presentation is seen as a recognition of Innate Pharma's clinical pipeline, particularly its Nectin-4 ADC (IPH4502), which could accelerate the development of its differentiated therapies to meet high unmet medical needs in the market.
- Industry Collaboration Platform: The AACR event brings together venture capitalists, investment bankers, and biopharmaceutical leaders, providing Innate Pharma with a valuable opportunity to connect with potential investors and partners, potentially facilitating future collaborations and funding support.
- Global Impact: As a global clinical-stage biotechnology company, Innate Pharma's presentation not only enhances its visibility in the field of oncology immunotherapy but may also pave the way for future innovative drug development, strengthening its competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.390
Low
5.00
Averages
6.50
High
8.00
Current: 1.390
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma to Present at AACR Oncology Event
- Key Presentation Opportunity: Innate Pharma's COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego, California, showcasing the company's innovative advancements in oncology drug development, which is expected to attract attention from investors and analysts.
- Clinical Pipeline Recognition: This presentation is seen as a recognition of Innate Pharma's clinical pipeline, particularly its Nectin-4 ADC (IPH4502), which could accelerate the development of its differentiated therapies to meet high unmet medical needs in the market.
- Industry Collaboration Platform: The AACR event brings together venture capitalists, investment bankers, and biopharmaceutical leaders, providing Innate Pharma with a valuable opportunity to connect with potential investors and partners, potentially facilitating future collaborations and funding support.
- Global Impact: As a global clinical-stage biotechnology company, Innate Pharma's presentation not only enhances its visibility in the field of oncology immunotherapy but may also pave the way for future innovative drug development, strengthening its competitive position in the market.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, where its executive team will engage in one-on-one meetings with investors, aiming to enhance investor relations and increase company visibility.
- Innovative Drug Development: The company is advancing multiple immunotherapies for cancer, including IPH4502 and lacutamab, focusing on areas of high unmet medical need, which will help establish a competitive edge in the crowded biopharmaceutical market.
- Strategic Partnerships: Innate Pharma has formed collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only bolster its R&D capabilities but also provide strong support for the market introduction of its innovative therapies.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, Innate Pharma's global footprint enables it to better address diverse market demands and drive its internationalization strategy.
See More
Innate Pharma Files 2025 Universal Registration Document
- Registration Document Filing: Innate Pharma filed its 2025 Universal Registration Document with the French market authority on April 1, 2026, which includes the annual financial and management reports, ensuring compliance and enhancing investor transparency.
- U.S. Report Submission: On the same day, Innate Pharma also submitted its Form 20-F annual report for 2025 to the SEC, further expanding its compliance in the U.S. market and boosting trust among international investors.
- Innovative Drug Development: The company focuses on developing immunotherapies for cancer patients, advancing multiple potential first-in-class assets, including IPH4502 and lacutamab, aimed at addressing high unmet medical needs and enhancing market competitiveness.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies like Sanofi and AstraZeneca, driving innovation in immuno-oncology and further solidifying its position in the biotechnology sector.
See More
Innate Pharma Reports FY 2025 Financial Results
- Financial Performance: Innate Pharma reported a FY 2025 GAAP EPS of -€0.55, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Revenue Decline: The company generated revenue of €9.01M, a 55.2% year-over-year decrease, suggesting a substantial weakening in market demand for its products or services, which could impact future growth potential.
- Cash Position: As of December 31, 2025, Innate Pharma holds a cash position of €44.8 million, with an anticipated cash runway extending until the end of Q3 2026, demonstrating the company's short-term survival capability.
- Future Outlook: Despite the current poor financial performance, the company must focus on cash flow management to ensure competitiveness in future R&D and marketing efforts.
See More
Innate Pharma Reports 2025 Financials and Clinical Trial Updates
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in H2 2026, contingent on ongoing negotiations for non-dilutive financing options, indicating the company's commitment to addressing unmet needs in cutaneous T-cell lymphoma.
- Financial Overview: As of December 31, 2025, Innate Pharma reported cash and cash equivalents of €44.8 million, a significant drop from €91.1 million in 2024, with an anticipated cash runway extending until Q3 2026, highlighting financial management challenges.
- Revenue Decline: The company generated €9.0 million in revenue for 2025, down 55.2% from €20.1 million in 2024, primarily due to a sharp decrease in collaboration and licensing income from AstraZeneca and Sanofi, reflecting challenges in its commercialization efforts.
- R&D Spending Adjustments: Research and development expenses totaled €43.6 million in 2025, a 16.1% decrease from €52.0 million in 2024, indicating cost control measures that may impact future clinical progress and competitive positioning.
See More
Innate Pharma to Host Financial Results Conference Call
- Conference Call Announcement: Innate Pharma will hold a conference call on March 26, 2026, at 2 p.m. CET / 9 a.m. EDT to discuss its financial results for the year ending December 31, 2025, which is expected to attract significant investor and analyst interest.
- Executive Participation: The call will feature key executives, including CEO Jonathan Dickinson and CFO Frédéric Lombard, highlighting the leadership's commitment to financial transparency and aiming to bolster investor confidence.
- Webcast Details: The event will be available via live webcast, with participants able to access it through the provided link, and a replay will be available on the company’s website for 90 days, ensuring that those unable to attend live can still access the information.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology company focused on developing cancer immunotherapies, advancing a portfolio of differentiated potential first and/or best-in-class assets, which underscores the company's strategic positioning in addressing high unmet medical needs.
See More
Innate Pharma to Present at AACR Oncology Event
- Key Presentation Opportunity: Innate Pharma's COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego, California, showcasing the company's innovative advancements in oncology drug development, which is expected to attract attention from investors and analysts.
- Clinical Pipeline Recognition: This presentation is seen as a recognition of Innate Pharma's clinical pipeline, particularly its Nectin-4 ADC (IPH4502), which could accelerate the development of its differentiated therapies to meet high unmet medical needs in the market.
- Industry Collaboration Platform: The AACR event brings together venture capitalists, investment bankers, and biopharmaceutical leaders, providing Innate Pharma with a valuable opportunity to connect with potential investors and partners, potentially facilitating future collaborations and funding support.
- Global Impact: As a global clinical-stage biotechnology company, Innate Pharma's presentation not only enhances its visibility in the field of oncology immunotherapy but may also pave the way for future innovative drug development, strengthening its competitive position in the market.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, where its executive team will engage in one-on-one meetings with investors, aiming to enhance investor relations and increase company visibility.
- Innovative Drug Development: The company is advancing multiple immunotherapies for cancer, including IPH4502 and lacutamab, focusing on areas of high unmet medical need, which will help establish a competitive edge in the crowded biopharmaceutical market.
- Strategic Partnerships: Innate Pharma has formed collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only bolster its R&D capabilities but also provide strong support for the market introduction of its innovative therapies.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, Innate Pharma's global footprint enables it to better address diverse market demands and drive its internationalization strategy.
See More
Innate Pharma Files 2025 Universal Registration Document
- Registration Document Filing: Innate Pharma filed its 2025 Universal Registration Document with the French market authority on April 1, 2026, which includes the annual financial and management reports, ensuring compliance and enhancing investor transparency.
- U.S. Report Submission: On the same day, Innate Pharma also submitted its Form 20-F annual report for 2025 to the SEC, further expanding its compliance in the U.S. market and boosting trust among international investors.
- Innovative Drug Development: The company focuses on developing immunotherapies for cancer patients, advancing multiple potential first-in-class assets, including IPH4502 and lacutamab, aimed at addressing high unmet medical needs and enhancing market competitiveness.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies like Sanofi and AstraZeneca, driving innovation in immuno-oncology and further solidifying its position in the biotechnology sector.
See More
Innate Pharma Reports FY 2025 Financial Results
- Financial Performance: Innate Pharma reported a FY 2025 GAAP EPS of -€0.55, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Revenue Decline: The company generated revenue of €9.01M, a 55.2% year-over-year decrease, suggesting a substantial weakening in market demand for its products or services, which could impact future growth potential.
- Cash Position: As of December 31, 2025, Innate Pharma holds a cash position of €44.8 million, with an anticipated cash runway extending until the end of Q3 2026, demonstrating the company's short-term survival capability.
- Future Outlook: Despite the current poor financial performance, the company must focus on cash flow management to ensure competitiveness in future R&D and marketing efforts.
See More
Innate Pharma Reports 2025 Financials and Clinical Trial Updates
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in H2 2026, contingent on ongoing negotiations for non-dilutive financing options, indicating the company's commitment to addressing unmet needs in cutaneous T-cell lymphoma.
- Financial Overview: As of December 31, 2025, Innate Pharma reported cash and cash equivalents of €44.8 million, a significant drop from €91.1 million in 2024, with an anticipated cash runway extending until Q3 2026, highlighting financial management challenges.
- Revenue Decline: The company generated €9.0 million in revenue for 2025, down 55.2% from €20.1 million in 2024, primarily due to a sharp decrease in collaboration and licensing income from AstraZeneca and Sanofi, reflecting challenges in its commercialization efforts.
- R&D Spending Adjustments: Research and development expenses totaled €43.6 million in 2025, a 16.1% decrease from €52.0 million in 2024, indicating cost control measures that may impact future clinical progress and competitive positioning.
See More
Innate Pharma to Host Financial Results Conference Call
- Conference Call Announcement: Innate Pharma will hold a conference call on March 26, 2026, at 2 p.m. CET / 9 a.m. EDT to discuss its financial results for the year ending December 31, 2025, which is expected to attract significant investor and analyst interest.
- Executive Participation: The call will feature key executives, including CEO Jonathan Dickinson and CFO Frédéric Lombard, highlighting the leadership's commitment to financial transparency and aiming to bolster investor confidence.
- Webcast Details: The event will be available via live webcast, with participants able to access it through the provided link, and a replay will be available on the company’s website for 90 days, ensuring that those unable to attend live can still access the information.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology company focused on developing cancer immunotherapies, advancing a portfolio of differentiated potential first and/or best-in-class assets, which underscores the company's strategic positioning in addressing high unmet medical needs.
See More
